论文部分内容阅读
目的探讨采用依帕司他治疗糖尿病周围神经病变的临床疗效及不良反应。方法对86例2型糖尿病合并周围神经病变患者进行控制血糖和口服依帕司他片(50mgtid×3周)的治疗,3周疗程结束后观察周围神经病变症状学评分、运动神经传导速度(MNCV)及感觉神经传导速度(SNCV)。结果治疗后周围神经病变的各种症状评分均明显低于治疗前(P均<0.05),治疗后尺神经、胫神经和正中神经MNCV及SNCV均明显高于治疗前(P均<0.05),治疗总有效率为90.70%。仅3例患者出现短时间轻度发热、恶心,未予处理自行缓解,无其他不良反应发生。结论依帕司他治疗糖尿病周围神经病变具有较好的临床疗效,不良反应少且轻。
Objective To investigate the clinical efficacy and adverse reactions of epalrestat in the treatment of diabetic peripheral neuropathy. Methods Eighty-six patients with type 2 diabetes mellitus and peripheral neuropathy underwent glycemic control and oral epalrestat (50 mgtid × 3 weeks). After 3 weeks of treatment, symptomology score of peripheral neuropathy, motor nerve conduction velocity (MNCV ) And sensory nerve conduction velocity (SNCV). Results After treatment, the scores of various symptoms of peripheral neuropathy were significantly lower than those before treatment (all P <0.05). MNCV and SNCV of ulnar nerve, tibial nerve and median nerve were significantly higher than those before treatment (all P <0.05) The total effective rate was 90.70%. Only 3 patients with mild fever for a short time, nausea, without treatment to ease, no other adverse reactions. Conclusion Epalrestat has good clinical efficacy in the treatment of diabetic peripheral neuropathy with less and less adverse reactions.